Abbott Laboratories ownership: Vanguard discloses 10.05% ABT stake
The Vanguard Group has updated its ownership disclosure for Abbott Laboratories common stock.
Rhea-AI Filing Summary
The Vanguard Group has updated its ownership disclosure for Abbott Laboratories common stock. Vanguard reports beneficial ownership of 174,894,079 Abbott shares, representing 10.05 % of the outstanding common stock. Vanguard reports no sole voting power, with 10,372,669 shares subject to shared voting power, and the ability to dispose of 158,240,243 shares on a sole basis and 16,653,836 shares on a shared basis. The filing states that Vanguard holds these securities in the ordinary course of business as an investment adviser, not for the purpose of changing or influencing control of Abbott. Vanguard’s clients, including registered investment companies and other managed accounts, have the right to receive dividends and sale proceeds, and no single other person has an interest in more than 5 % of the class.
Positive
- None.
Negative
- None.
FAQ
What dispositive power does The Vanguard Group report over its Abbott (ABT) holdings?
Is The Vanguard Group’s stake in Abbott Laboratories (ABT) considered passive?
Who benefits economically from The Vanguard Group’s Abbott Laboratories (ABT) holdings?
Under what classification is The Vanguard Group filing this Schedule 13G/A for Abbott (ABT)?
AI-generated analysis. How Rhea-AI works. Not financial advice.